Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Retrospective Study of Pimavanserin in Patients with Parkinson’s Disease: a Single-center Experience.
Movement Disorders
Movement Disorders Posters (7:00 AM-5:00 PM)
061

To summarize a single-center experience with pimavanserin in Parkinson’s disease (PD) patients.
Psychosis in PD has been well recognized. Pimavanserin has been approved for treating PD psychosis (PDP). However, real-world data is limited on the efficacy and tolerability of pimavanserin in PD patients.

A retrospective chart review was carried out to examine the effect of pimavanserin on PDP patients. We also compared the efficacy and tolerability of pimavanserin in PDP patients with cognitive impairment or DBS.
We identified 45 patients treated with pimavanserin (62.2% male, mean age 75.8±7.5 years). Improvement in psychosis was reported in 71.4% of patients, while deterioration was documented in 7.1%. Patients responsive to pimavanserin had a relatively shorter PD course (p=0.010), PD to psychosis interval (p=0.020), PD to pimavanserin initiation interval (p=0.007), and PD to DBS interval (p=0.025). The side effects (SE) rate was 30.6% (11/36). The most common SE was gait disorders 13.9% (5/36). 41.7% (15/36) discontinued pimavanserin due to SE, no response, financial issues, resolution of symptoms, and concern about SE. 20.0% (9/45) had tried other antipsychotics, of which the most common medication was quetiapine. Cognitive impairment was highly prevalent (86.7%). There was no difference in the efficacy and SE rates of pimavanserin, the use of multiple antipsychotics, or duration of pimavanserin between patients with cognitive impairment and those without. 28.9% (13/45) of patients underwent DBS surgery. The efficacy rate of pimavanserin in the DBS group was 44.4% and the non-DBS group was 84.2%, not significantly different (p=0.068). The side effects (SE) reported were comparable between non-DBS (33.3%) and DBS patients (22.6%).
Pimavanserin is effective and tolerable in most PDP patients, including those with cognitive impairment or DBS. Patients with earlier PDP onset may have a better response to pimavanserin. Further prospective studies are needed to confirm these findings.
Authors/Disclosures
Luhua Wei
PRESENTER 		Luhua Wei has nothing to disclose.
Zhaoxia Wang, DO (Peking University First Hospital) No disclosure on file
Yining Huang, PhD (Peking University First Hospital) No disclosure on file
Sarah Farias (University of California, Davis) No disclosure on file
Alexandra O. Duffy, MD, FÂ鶹´«Ã½Ó³»­ (UC Davis Health) Dr. Duffy has nothing to disclose.
No disclosure on file
Vicki L. Wheelock, MD (UC Davis Department of Neurology) Dr. Wheelock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche Pharmaceuticals. Dr. Wheelock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for uniQure. Dr. Wheelock has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for PRIME Continuing Medical Â鶹´«Ã½Ó³»­.
Lin Zhang, MD, PhD, FÂ鶹´«Ã½Ó³»­ (UCDMC) Dr. Zhang has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for supernus. Dr. Zhang has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for supernus. The institution of Dr. Zhang has received research support from Michael J. Fox Foundation.